文献速递头颈外科

塞来昔布与头颈癌游离组织重建术后阿片类药物需求降低相关

Association of Celecoxib Use With Decreased Opioid Requirements After Head and Neck Cancer Surgery With Free Tissue Reconstruction.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2018-01-01

这项回顾性匹配队列研究纳入147例头颈癌游离组织重建患者,按围手术期是否使用塞来昔布分组,匹配分期和部位后共102例(塞来昔布组51例,对照组51例)。结果显示塞来昔布组口服、静脉及总阿片需求量均降低,且不增加手术或皮瓣相关并发症。

要点

  • 塞来昔布组口服、静脉及总阿片需求量均降低
  • 复合口腔切除患者中塞来昔布降低阿片需求更显著
  • 两组并发症发生率无显著差异

核心结论

  • 头颈癌游离组织重建术后使用塞来昔布与口服、静脉及总阿片需求量降低相关,且不增加手术或皮瓣相关并发症。

研究设计与样本

  • 回顾性匹配队列研究,2015年6月至2017年9月在一家学术癌症医院纳入147例头颈癌游离组织重建患者,按围手术期是否使用塞来昔布分组,匹配分期和部位后共102例(塞来昔布组51例,对照组51例)。

主要发现

  • 塞来昔布组与对照组相比,口服吗啡当量日均用量平均差异为9.9 mg/d(95% CI,-1.2至21.1)。
  • 静脉吗啡当量日均用量平均差异为3.9 mg/d(95% CI,1.0-6.8)。
  • 总吗啡当量日均用量平均差异为14 mg/d(95% CI,2.6-25.4)。
  • 按手术方式匹配后,复合口腔切除患者中塞来昔布组口服、静脉及总阿片用量平均差异分别为25 mg/d(95% CI,12.5-25.4)、3.4 mg/d(95% CI,1.5-5.5)和28.4 mg/d(95% CI,15.7-41.5)。
  • 两组并发症发生率无显著差异。

临床怎么用

  • 头颈癌游离组织重建术后可考虑使用塞来昔布以减少阿片类药物需求,且不增加手术或皮瓣相关并发症。

局限性

  • 本研究为回顾性匹配队列研究,样本量有限,结论需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Head and neck cancer (HNC) surgery with free tissue reconstruction is associated with considerable postoperative pain. Opioids are typically used but can have adverse effects, including respiratory depression and high rates of dependence and addiction. Safe alternative analgesics that minimize opioid requirements are beneficial in HNC surgery. OBJECTIVE: To investigate the association of celecoxib use with opioid requirements in the postoperative setting after HNC surgery with free tissue reconstruction. DESIGN, SETTING, AND PARTICIPANTS: A retrospective, matched-cohort study of 147 patients who had undergone HNC surgery with free tissue reconstruction between June 2015 and Sept 2017 in an academic cancer hospital. Patients were separated into groups based on whether celecoxib had been used perioperatively or not. These groups were then matched by stage and site resulting in 102 included participants (51 celecoxib, 51 control). MAIN OUTCOMES AND MEASURES: Oral, intravenous (IV), and total morphine equivalents used in the postoperative setting per patient per day. RESULTS: There were 51 patients in the celecoxib cohort (19 women and 32 men) and 51 patients in the control cohort (20 women and 31 men) who met inclusion criteria after clinicopathologic data were matched. The mean age of the celecoxib and control cohorts was 61.6 years and 66.1 years, respectively. Treatment with celecoxib in the postoperative setting was associated with decreased mean use of opioids in oral (mean difference, 9.9 mg/d; 95% CI, -1.2 to 21.1), IV (mean difference, 3.9 mg/d; 95% CI, 1.0-6.8), and total (mean difference, 14 mg/d; 95% CI, 2.6-25.4) amount of morphine equivalents per day. When patients were matched to surgical procedure, the effect was more significant. Patients who underwent composite oral resection and received celecoxib had decreased opioid use in oral (mean difference, 25 mg/d; 95% CI, 12.5-25.4), IV (mean difference, 3.4 mg/d; 95% CI, 1.5-5.5), and total (mean difference, 28.4 mg/d; 95% CI, 15.7-41.5) amounts compared with those in the control group. There was no significant difference in complication rates between the 2 cohorts. CONCLUSIONS AND RELEVANCE: Use of celecoxib after head and neck cancer surgery and reconstruction with free tissue transfer was associated with a decrease in oral, IV, and total opioid requirements without increasing surgical or flap-related complications.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Carpenter PS, Shepherd HM, McCrary H, et al. Association of Celecoxib Use With Decreased Opioid Requirements After Head and Neck Cancer Surgery With Free Tissue Reconstruction. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 29710229. doi:10.1001/jamaoto.2018.0284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。